secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001193125-23-139057
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan enters $30M upfront collaboration with Amgen to identify Crohn's disease T-cell targets
--------------------------------------------------------------------------------

- TScan receives $30M upfront; eligible for over $500M in development and commercial milestone payments.
- Amgen gains exclusive global rights to develop and commercialize therapeutics from discovered targets.
- Amgen holds an option to expand the collaboration to include ulcerative colitis under predefined terms.
- TScan also earns tiered single-digit royalties on net sales from any products developed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523139057/0001193125-23-139057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523139057/d420303d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-139057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer